Trevi Therapeutics Inc

Market Cap

$2B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$13.50+$1.61 (+13.54%)

Jun 8, 2026

52W High $15.4052W Low $5.47

Company Details

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung ...

CEO

—

IPO Date

May 7, 2019

Website

www.trevitherapeutics.com

Key Metrics TTM

Revenue

-100.0% YoY

Net Income

-$46M

EPS (Diluted)

Free Cash Flow

-$32M

Revenue / Share

$0.00

Gross Margin

Operating Margin

Net Margin

FCF Margin

P/S

P/E

Earnings Reports

Q1 2026

May 5, 2026

FY 2025

Mar 17, 2026

Q4 2025

Mar 17, 2026

$0-100.0%

Q3 2025

Nov 13, 2025

Q2 2025

Aug 7, 2025

Revenue & Profitability

Valuation

Operating Cash Flow

CapEx Spend

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

War Chest

Shares Outstanding

Revenue Per Employee

Revenue / Employee